Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
HPB (Oxford) ; 22(7): 939-949, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32349925

RESUMEN

BACKGROUND: This meta-analysis was performed by analyzing randomized controlled trials (RCTs) to assess the potential prognostic value of adjuvant chemotherapy (ACT) for patients with resected biliary tract cancers (BTCs). METHODS: PubMed, EMBASE, and the Cochrane Library were searched for relevant articles published. Only RCTs affected by tumors of gallbladder, intrahepatic, perihilar, and distal bile ducts were considered. Data were pooled using a random-effects model. The primary endpoint of the study was overall survival (OS). RESULTS: The study identified 1192 patients who met the inclusion and exclusion criteria. ACT had nearly reached a significant better OS (HR, 0.88; 95% CI, 0.77-1.01; P = 0.07) and achieved a significant better RFS (HR, 0.83; 95% CI, 0.69-0.99; P = 0.04). The effectiveness of ACT for OS was significantly modified by fluorouracil-based ACT (HR, 0.83; 95% CI, 0.70-0.99; P = 0.04), but not by gemcitabine-based ACT (HR, 0.91; 95% CI, 0.74-1.12; P = 0.36). The survival benefit was also not modified by primary disease site, resection margin status, and lymph node status. CONCLUSIONS: ACT is correlated with favorable relapse-free survival compared with non-ACT for resected BTCs patients. Fluorouracil-based ACT could be viewed as a standard practice for resected BTCs patients regardless of the primary cancer site, lymph node or margin status.


Asunto(s)
Neoplasias del Sistema Biliar , Recurrencia Local de Neoplasia , Neoplasias del Sistema Biliar/tratamiento farmacológico , Neoplasias del Sistema Biliar/cirugía , Quimioterapia Adyuvante , Fluorouracilo/efectos adversos , Humanos , Ensayos Clínicos Controlados Aleatorios como Asunto
2.
J Microbiol Biotechnol ; 18(1): 118-23, 2008 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-18239427

RESUMEN

A new method for antimicrobial susceptibility testing of in vitro-cultured bacteria on an ordinary fluorescence spectrometer was developed. The viable bacteria reduced 3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) to produce insoluble particles that displayed intense resonance scattering light (RSL). The assay showed a linear relationship between the number of viable bacteria and the intensity of resonance scattering light. Dead bacteria were unable to reduce MTT. Methicillin-resistant Staphylococcus aureus exposed to flavonoids from Marchantia convoluta showed a flavonoids concentration-dependent inhibition of the ability to reduce MTT. In the assay, less than 12 h were required to attain susceptibility results and fewer bacteria were utilized than in traditional methods. The RLS technique could, in combination with the MTT assay, be a rapid and sensitive measuring method to determine the in vitro activity of new antimicrobials.


Asunto(s)
Antibacterianos/farmacología , Luz , Pruebas de Sensibilidad Microbiana/métodos , Dispersión de Radiación , Staphylococcus aureus/efectos de los fármacos , Antibacterianos/química , Colorantes/metabolismo , Flavonoides/química , Flavonoides/farmacología , Humanos , Marchantia/química , Resistencia a la Meticilina , Oxidación-Reducción , Extractos Vegetales/química , Extractos Vegetales/farmacología , Espectrometría de Fluorescencia/instrumentación , Staphylococcus aureus/metabolismo , Sales de Tetrazolio/metabolismo , Tiazoles/metabolismo
3.
Zhongguo Zhong Yao Za Zhi ; 29(10): 970-3, 2004 Oct.
Artículo en Chino | MEDLINE | ID: mdl-15631086

RESUMEN

OBJECTIVE: To study the reverse effect of ligustrazine (TMP) on HepG2/ADM, a herd of hepatocellular carcinoma cell, multidrug resistance (MDR) and the influence of P-gp170 expression. METHOD: The reverse effect of ligustrazine on HepG2/ADM cell was observed, with the methods of cell culture, MTT's analyze, RT-PCR and Flow cytometric, etc. RESULT: Ligustrazine could make MDR of cell line of HepG2/ADM reduce the expression of P-gp170, enhance the density of adriamycin in cell and increase the adriamycin's cytotoxicity. With the Flow cytometric, the results of RT-PCR showed the transcriptional activity of the MDR1 decreased. CONCLUSION: Ligustrazine can reverse MDR of HCC cell line of HepG2/ADM and has prospect in clinical use.


Asunto(s)
Carcinoma Hepatocelular/patología , Resistencia a Múltiples Medicamentos/efectos de los fármacos , Glicoproteínas/metabolismo , Neoplasias Hepáticas/patología , Pirazinas/farmacología , Subfamilia B de Transportador de Casetes de Unión a ATP , Bloqueadores de los Canales de Calcio/farmacología , Carcinoma Hepatocelular/metabolismo , Línea Celular Tumoral , Citotoxicidad Inmunológica/efectos de los fármacos , Doxorrubicina/metabolismo , Doxorrubicina/farmacología , Resistencia a Antineoplásicos/efectos de los fármacos , Genes MDR , Humanos , Neoplasias Hepáticas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA